Q1 FY26 Activities Report and Appendix 4C

• Quarterly sales rose by 38% compared to the corresponding quarter in FY25
• Portfolio Expansion: EmpliQ product ranges launched with first sale of the EmpliQ dermal
• Product Pipeline Progress: Continued progress toward NervAlign® Nerve Conduit market entry

ReNerve Limited, an Australian biotechnology company developing innovative products for peripheral nerve injury repair, presented its Quarterly Report for the period ended 30 September 2025. During the quarter, the company continued to build commercial momentum, with sales for the quarter increasing by 38% relative to the corresponding period in FY25. The company launched its EmpliQ human tissue product ranges and achieved the first sale of the EmpliQ dermal product, with first sale of the amniotic tissue products occurring in October. The company also showcased the EmpliQ products at the American Society for Surgery of the Hand (ASSH) conference in early October. The market availability of these products will contribute to ongoing sales growth and form an important part of ReNerve's broader commercial strategy. The company also made progress toward the NervAlign® Nerve Conduit market entry, with the finalization of the production hardware and process for the first conduit products in the range. First production batches are expected during the January 2026 quarter, with market release expected shortly thereafter. The company's net cash position at the end of the quarter was $3.27 million.